Phraxis, Inc., a leader in vascular access innovation, announced the successful completion of the first commercial case using the EndoForce Anastomotic Connector, marking a historic milestone in the treatment of dialysis patients worldwide.

The procedure, performed by Dr. Ari Kramer, Vascular Access Surgeon and early clinical pioneer of EndoForce, took place at Spartanburg Regional Medical Centre in Spartanburg, South Carolina.

EndoForce, recently granted U.S. Food and Drug Administration (FDA) approval, is the first device of its kind designed to simplify vascular access creation by replacing hand-sewn surgical sutures with a precise, reproducible connector. The technology is compatible with all PTFE grafts and was studied extensively in the company's pivotal clinical trial.

"Every decision we make in the OR comes back to the patient. With EndoForce, we have a tool designed to make graft-to-vein connections more predictable and efficient. Launching the first commercial case at Spartanburg Regional is a meaningful step forward for our dialysis community," said Dr. Ari Kramer, Vascular Access Surgeon, Spartanburg Regional Medical Centre.

"This achievement is the result of more than a decade of relentless innovation, collaboration with world-class surgeons, and unwavering commitment to patient outcomes. We are proud to see EndoForce enter the clinical arena—where it can make a meaningful difference," said Dr. Alex Yevzlin, Founder and Chief Executive Officer of Phraxis, Inc.